Literature DB >> 7693282

The effects of single and repeated anorectic doses of 5-hydroxytryptamine uptake inhibitors on indole levels in rat brain.

S Caccia1, M Anelli, A M Codegoni, C Fracasso, S Garattini.   

Abstract

1. The effects of acute and repeated equiactive anorectic doses (ED50) of recently marketed 5-hydroxytryptamine (5-HT) uptake inhibitors on the content of brain indoles were compared in rats in relation to the brain regional concentrations of unchanged drug and its known active metabolite. 2. Single intraperitoneal (i.p.) doses of the anorectic ED50 of fluoxetine (35 mumol kg-1), fluvoxamine (60 mumol kg-1), paroxetine (20 mumol kg-1) and sertraline (49 mumol kg-1) slightly reduced brain 5-hydroxyindoleacetic acid (5-HIAA), with regional differences, this being compatible with 5-HT uptake blockade. Only fluvoxamine and sertraline significantly enhanced the content of 5-HT in the cortex. 3. The regional sensitivity to the acute effect of a given drug was not related to any preferential drug distribution, as these compounds distributed almost uniformly in the brain areas considered (cortex, striatum and hippocampus). 4. Repeating the same doses twice daily, i.p. for 14 days, however gave a different picture, fluvoxamine having little or no effect on the content of indoles and fluoxetine, paroxetine and sertraline lowering both 5-HT and 5-HIAA in all the brain regions compared to pair-fed control animals, 1 h after the last dose. 5. One week later only fluoxetine-treated animals still had reduced brain 5-HT, this probably being related to the accumulation of its main metabolite norfluoxetine in rat brain after chronic dosing. 6. Further studies on the relationship between the long-term neurochemical changes and anorectic activity are required but it appears from these results that anorectic drugs with similar acute effects on 5-HT uptake may differ in their long-term effects on 5-HT mechanisms.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7693282      PMCID: PMC2175989          DOI: 10.1111/j.1476-5381.1993.tb13817.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  23 in total

Review 1.  Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness.

Authors:  P Benfield; A Ward
Journal:  Drugs       Date:  1986-10       Impact factor: 9.546

2.  Effects of zimelidine on serotoninergic and noradrenergic neurons after repeated administration in the rat.

Authors:  S B Ross; H Hall; A L Renyi; D Westerlund
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

3.  Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves.

Authors:  A DeLean; P J Munson; D Rodbard
Journal:  Am J Physiol       Date:  1978-08

4.  Effect of zimelidine, a new antidepressant, on appetite and body weight.

Authors:  R J Simpson; D J Lawton; M H Watt; B Tiplady
Journal:  Br J Clin Pharmacol       Date:  1981-01       Impact factor: 4.335

5.  Application of the dual-cell coulometric detector: a method for assaying monoamines and their metabolites.

Authors:  G Achilli; C Perego; F Ponzio
Journal:  Anal Biochem       Date:  1985-07       Impact factor: 3.365

6.  "Treatment of obesity by femoxetine a selective 5 HT reuptake inhibitor'.

Authors:  J Smedegaard; P Christiansen; B Skrumsager
Journal:  Int J Obes       Date:  1981

7.  Anorectic activity of fluoxetine and norfluoxetine in rats: relationship between brain concentrations and in-vitro potencies on monoaminergic mechanisms.

Authors:  S Caccia; A Bizzi; G Coltro; C Fracasso; E Frittoli; T Mennini; S Garattini
Journal:  J Pharm Pharmacol       Date:  1992-03       Impact factor: 3.765

8.  Anorectic activity of fluoxetine and norfluoxetine in mice, rats and guinea-pigs.

Authors:  M Anelli; A Bizzi; S Caccia; A M Codegoni; C Fracasso; S Garattini
Journal:  J Pharm Pharmacol       Date:  1992-08       Impact factor: 3.765

9.  Effects of short- and long-term administration of fluoxetine on the monoamine content of rat brain.

Authors:  S Caccia; C Fracasso; S Garattini; G Guiso; S Sarati
Journal:  Neuropharmacology       Date:  1992-04       Impact factor: 5.250

10.  Sertraline, 1S,4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthylamine, a new uptake inhibitor with selectivity for serotonin.

Authors:  B K Koe; A Weissman; W M Welch; R G Browne
Journal:  J Pharmacol Exp Ther       Date:  1983-09       Impact factor: 4.030

View more
  12 in total

1.  Regional differences in the effect of the combined treatment of WAY 100635 and fluoxetine: an in vivo microdialysis study.

Authors:  I Malagié; A C Trillat; E Douvier; M C Anmella; M C Dessalles; C Jacquot; A M Gardier
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-12       Impact factor: 3.000

Review 2.  Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications.

Authors:  S Caccia
Journal:  Clin Pharmacokinet       Date:  1998-04       Impact factor: 6.447

3.  Plasma serotonin levels are associated with antidepressant response to SSRIs.

Authors:  Amanda Holck; Owen M Wolkowitz; Sindy H Mellon; Victor I Reus; J Craig Nelson; Åsa Westrin; Daniel Lindqvist
Journal:  J Affect Disord       Date:  2019-02-26       Impact factor: 4.839

Review 4.  Oscillatory serotonin function in depression.

Authors:  Ronald M Salomon; Ronald L Cowan
Journal:  Synapse       Date:  2013-05-21       Impact factor: 2.562

5.  Chronic SSRI treatment exacerbates serotonin deficiency in humanized Tph2 mutant mice.

Authors:  William B Siesser; Benjamin D Sachs; Amy J Ramsey; Tatyana D Sotnikova; Jean-Martin Beaulieu; Xiaodong Zhang; Marc G Caron; Raul R Gainetdinov
Journal:  ACS Chem Neurosci       Date:  2012-10-01       Impact factor: 4.418

6.  A genetic rat model of depression, Flinders sensitive line, has a lower density of 5-HT(1A) receptors, but a higher density of 5-HT(1B) receptors, compared to control rats.

Authors:  Kyoko Nishi; Kazuya Kanemaru; Mirko Diksic
Journal:  Neurochem Int       Date:  2008-12-13       Impact factor: 3.921

7.  Brain region-specific effects of short-term treatment with duloxetine, venlafaxine, milnacipran and sertraline on monoamine metabolism in rats.

Authors:  Katsumasa Muneoka; Yukihiko Shirayama; Morikuni Takigawa; Seiji Shioda
Journal:  Neurochem Res       Date:  2008-08-27       Impact factor: 3.996

8.  Chronic citalopram administration causes a sustained suppression of serotonin synthesis in the mouse forebrain.

Authors:  Gerard Honig; Minke E Jongsma; Marieke C G van der Hart; Laurence H Tecott
Journal:  PLoS One       Date:  2009-08-27       Impact factor: 3.240

9.  Selective serotonin reuptake inhibitor antidepressant treatment discontinuation syndrome: a review of the clinical evidence and the possible mechanisms involved.

Authors:  Thibault Renoir
Journal:  Front Pharmacol       Date:  2013-04-16       Impact factor: 5.810

10.  Effects of psychotropic agents on extinction of lever-press avoidance in a rat model of anxiety vulnerability.

Authors:  Xilu Jiao; Kevin D Beck; Amanda L Stewart; Ian M Smith; Catherine E Myers; Richard J Servatius; Kevin C H Pang
Journal:  Front Behav Neurosci       Date:  2014-09-15       Impact factor: 3.558

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.